Skip to main content
editorial
. 2017 Oct 5;4(9-10):120–121. doi: 10.18632/oncoscience.366

Figure 1. A list of (X)-3s made by the DNL® with a schematic showing the site-specific conjugation between a dimer of anti-X Fab and a monomer of anti-CD3 scFv via the fused DDD2 and AD2 peptides.

Figure 1